Jean-Yves Douillard MD, PhD
Professor Emeritus, Medical Oncology, University of Nantes; Senior Advisor, Integrated Centers of Oncology (ICO), Nantes, FranceDr. Jean-Yves Douillard is a leading international expert in lung cancer and gastrointestinal oncology, and, over the course of a long career, he has held a number of leadership positions, including at the University of Nantes, where he was Professor in Medical Oncology, and at the Integrated Centers of Oncology (ICO) in Nantes, as Head of the Medical Oncology Department and later as Director of Clinical and Translational Research. He has also held senior ESMO positions, serving as Educational Committee Chair and as a member of the Executive Board.
Throughout his career, Dr. Douillard has led clinical trials in lung cancer and gastrointestinal tumors and has investigated targeted therapies, publishing his work in leading scientific journals. His clinical interests also include early drug development and translational research.
Currently, Dr. Doullard is serving as Senior Advisor in early clinical trial research at the Integrated Centers of Oncology.
Recent Contributions to PracticeUpdate:
- Five-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC
- Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive NSCLC
- 2021 Top Story in Lung Cancer: Changes in Paradigm for Potentially Curable NSCLC
- ESMO Immuno-Oncology 2021: Recommendations From Dr. Jean-Yves Douillard for Non–Small Cell Lung Cancer
- Revisiting Neoadjuvant Therapy in NSCLC
- ESMO 2021: Recommendations From Dr. Jean-Yves Douillard for Lung Cancer
- ASCO 2021: Abstract Recommendations From Dr. Jean-Yves Douillard for Lung Cancer
- Pemetrexed Plus Platinum ± Pembrolizumab in Patients With Previously Untreated Metastatic Nonsquamous NSCLC
- Pembrolizumab vs Chemotherapy for PD-L1–High Metastatic NSCLC
- AACR 2021: Addition of Nivolumab to Neoadjuvant Chemotherapy Increases Pathologic Complete Response to Non-Small Cell Lung Cancer